- Kymera Therapeutics director Elena Ridloff sold 13,000 shares on March 31-April 1.
- Sales were priced at about $85.37 per share on March 31.
- Additional shares sold April 1 were priced at about $85.19-$86.05 per share.
- Ridloff’s direct holdings fell to 0 shares following transactions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-138372), on April 01, 2026, and is solely responsible for the information contained therein.
Comments